drugset / Trial / NCT02542930

Abscopal Effect for Metastatic Non-small Cell Lung Cancer.

NCT02542930

NaSingle-groupOpen-labelTreatment

Summary

Patients with Non-small cell lung cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1. To observe immunity-mediated tumor response outside the radiation field (abscopal effect) after chemoradiotherapy of a metastatic site in metastatic Non-small cell lung cancer patients. 2. To induce the efficacy (effectiveness) of a new combination of therapy, chemoradiotherapy and thymalfasin for heavily pretreated, metastatic Non-small cell lung cancer patients; 3. To explore the role of PET/CT scanning to assess tumor response/abscopal effect. This study will help find out what abscopal effects (good or bad) the combination of radiotherapy and thymalfasin has on metastatic Non-small cell lung cancer.

Timeline

Start
2016-01
Primary completion
2018-12
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Thymalfasin Peptide